Skip to main content
Fig. 3 | Alzheimer's Research & Therapy

Fig. 3

From: A pilot study to evaluate the effect of CT1812 treatment on synaptic density and other biomarkers in Alzheimer’s disease

Fig. 3

Change in clinical outcome measures through 24 weeks. Subjects were assessed using the ADAS-Cog11 (A), ADCS-ADL (B), MMSE (C), and CDR-SB (D) at baseline, 6, 12, 18 and 24 weeks. Data shown are LS Mean difference change (at 24 weeks) from baseline and SE from the linear mixed-effects model for repeated measures (MMRM). There were no differences throughout the 5 study visits. No significant differences were seen between any of the treatment groups in change from baseline through 24 weeks

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193